COVID-19 Pandemic Pushes EU To Extend GMP/GDP Certificate Validity
As the COVID-19 pandemic continues to pose difficulties in conducting on-site inspections to check compliance with good manufacturing and distribution requirements, regulators in the EU have extended the validity of existing certificates and time-limited authorizations till the end of next year.
You may also be interested in...
Drug companies unable to continue with standard reporting of suspected adverse reactions to the EU pharmacovigilance database can temporarily prioritize their reporting activities to focus on COVID-19 related safety events.
The EMA is inviting feedback on its plans to ratify, with some caveats, a new framework on how to use patient preferences as input in medical product decision-making. The framework was developed under the EU’s public-private Innovative Medicines Initiative.
The COVID-19 pandemic has given a new impetus to Sweden’s ongoing efforts to support decentralized clinical trials.